|1.||Ponomarev, Vladimir: 1 article (10/2009)|
|2.||Labrinidis, Agatha: 1 article (10/2009)|
|3.||Hay, Shelley: 1 article (10/2009)|
|4.||Zannettino, Andrew C W: 1 article (10/2009)|
|5.||Zinonos, Irene: 1 article (10/2009)|
|6.||Liapis, Vasilios: 1 article (10/2009)|
|7.||Evdokiou, Andreas: 1 article (10/2009)|
|8.||Lee, Michelle: 1 article (10/2009)|
|9.||Diamond, Peter: 1 article (10/2009)|
|10.||Findlay, David M: 1 article (10/2009)|
10/01/2009 - "In the delayed treatment protocol, Apomab treatment resulted in the complete regression of advanced tibial tumors with progressive restoration of both trabecular and cortical bone leading to full resolution of osteolytic lesions. "
10/01/2009 - "In vivo, Apomab exerted remarkable tumor suppressive activity leading to complete regression of well-advanced mammary tumors. "
01/01/2009 - "Here, we aim to image tumor uptake of APOMAB (DAB4) and to define its biological correlates. "
08/01/2008 - "Apomab demonstrates preclinical activity against a range of solid tumors, both as monotherapy and in combination with cytotoxics. "
04/01/2008 - "These results provide structural and functional insight into the interaction of Apomab with DR5 and support further investigation of this antibody for cancer therapy."
|2.||Lung Neoplasms (Lung Cancer)
12/01/2008 - "Several lung cancer cell lines express DR5 and exhibit apoptosis in response to apomab in vitro. "
12/01/2008 - "To test apomab activity in a setting that may more closely mimic lung cancer pathology in patients, we developed a lung orthotopic model. "
12/01/2008 - "These results show a positive interaction of apomab with chemotherapy, evidenced by significant inhibition of tumor growth as well as improved survival, thus supporting further investigation of this therapeutic approach in lung cancer patients."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|4.||Breast Neoplasms (Breast Cancer)
10/01/2009 - "In this study, we assessed the cytotoxic effect of Apomab in vitro and evaluated its antitumor activity in murine models of breast cancer development and progression. "
10/01/2009 - "Apomab represents a potent immunotherapeutic agent with strong activity against the development and progression of breast cancer and should be evaluated in patients with primary and metastatic disease."
10/01/2009 - "In vitro, Apomab treatment induced apoptosis in a panel of breast cancer cell lines but was without effect on normal human primary osteoblasts, fibroblasts, or mammary epithelial cells. "
10/01/2009 - "Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer."
10/01/2009 - "In contrast, treatment with Apomab following an early treatment protocol inhibited both intraosseous and extraosseous tumor growth and prevented breast cancer-induced osteolysis. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
|1.||TNF-Related Apoptosis-Inducing Ligand Receptors
|4.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)